Clinical Efficacy of Ferulic Acid Piperazine Combined with Dapagliflozin in the Treatment of Type 2 Diabetic Nephropathy
Objective To retrospectively investigate the clinical efficacy of ferulic acid piperazine combined with dapagliflozin in the treatment of type 2 diabetic nephropathy(T2DN).Methods Medical records of 86 T2DN patients treated in the First People's Hospital of Zhengzhou from January 2022 to November 2023 were selected.Patients were divided into a control group(42 cases)and an observation group(44 cases)based on the treatment regimen.Both groups received conventional treatment and dapagliflozin,While the control group was treated with dapagliflozin,and the observation group was treated with dapagliflozin combined with ferulic acid piperazine.The blood glucose indicators[fasting blood glucose(FBG),glycosylated hemoglobin(HbA1c),2-hour postprandial blood glucose(2h PG)],renal function[serum creatinine(SCr),24-hour urinary microalbumin,estimated glomerular filtration rate(eGFR)],serum-related cytokines[β2-microglobulin(β2-MG),lipoprotein-associated phospholipase A2(Lp-PLA2),cystatin C(Cys-C),1,25-dihydroxyvitamin D3(1,25-(OH)2-D3)],and adverse reactions were compared between the two groups.Results After 4 and 8 weeks of treatment,the levels of FBG,HbA1c,and 2h PG in both groups decreased significantly compared to before treatment(P＜0.05);however,no significant difference was found between the two groups(P＞0.05).The levels of SCr and 24-hour urinary microalbumin decreased,while the levels of eGFR increased after 4 and 8 weeks of treatment in both groups,with the observation group showing lower levels of SCr and 24-hour urinary microalbumin and higher level of eGFR than the control group,indicating statistical significance(P＜0.05).After 4 and 8 weeks of treatment,the level of β2-MG,Lp-PLA2,and Cys-C decreased in both groups,with the observation group showing lower levels than the control group,which were statistically significant(P＜0.05).After 8 weeks of treatment,the levels of 1,25-(OH)2-D3 increased in both groups compared to before treatment,showing statistical significance(P＜0.05),but no significant difference was found between the two groups(P＞0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Ferulic acid piperazine combined with dapagliflozin in the treatment of T2DN can effectively reduce blood glucose,improve renal function,and has certain safety.
Type 2 DiabetesNephropathyFerulic Acid PiperazineDapagliflozin
万方数据
维普
